Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BGMA

- PMLiVE

Market access and reimbursement in key European markets

An introductory guide to European market access and reimbursement stakeholders and processes in France, Great Britain, Germany, Italy and Spain.

Mtech Access

- PMLiVE

Sandoz separates from Novartis as an independent spin-off company

The split allows Sandoz to strengthen its position in generics and biosimilars

- PMLiVE

Sandoz launches high-concentration biosimilar of AbbVie’s Humira in the US

Hyrimoz HCF is approved to treat indications including rheumatoid arthritis and Crohn’s disease

- PMLiVE

Sandoz and Just-Evotec Biologics announce multi-year biosimilar partnership

The Novartis unit will aim to expand its current pipeline of biosimilars to about 24 candidates

EU flag

EIT Health and IHI join forces to support health research and innovation across Europe

The organisations have signed a MoU to formalise the collaboration

- PMLiVE

Kate Shaw comments the appointment of an independent review on clinical trials in the UK.

The news comes after a report by the Association of the British Pharmaceutical Industry (ABPI) highlighted a 44% decline in industry clinical trials in the UK over the last five...

Innovative Trials

- PMLiVE

Sandoz launches ‘Act4Biosimilars’ initiative to address global health inequalities

The initiative wants to increase the global use of biosimilars by at least 30% by 2030

- PMLiVE

Nucleus Global launches Chrysalis Medical Communications, the network’s newest agency brand in Europe, with a unifying mission

Nucleus Global, the largest specialist medical communications network in the world, today launched Chrysalis in Europe with the mission of transforming medical communications together.Stuart Gilbert, Managing Director, said: “Chrysalis’s mission...

Nucleus Global

- PMLiVE

Biosimilars boosted by FDA’s landmark ruling for Boehringer’s Cyltezo

The FDA has approved Boehringer’s Cyltezo (adalimumab-adbm) as ‘interchangeable’ with Humira (adalimumab) in a landmark ruling

- PMLiVE

Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars

Competition created by biosimilars has delivered $9.8bn in savings over five years and could reduce patients’ out-of-pocket costs by $238m

- PMLiVE

Piloting a route to the biosimilars opportunities in Europe

Investigating the EU regulatory hurdles that life sciences companies face as they seek to improve patient access to biosimilar therapy

- PMLiVE

J&J’s single-dose COVID-19 vaccine secures approval from the UK’s MHRA

Vaccine was found to be 67% effective in preventing COVID-19 infection in a phase 3 study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links